2-chloro-N,N,5-trimethylnicotinamide | 178672-20-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-chloro-N,N,5-trimethylnicotinamide
• 英文别名: 2-chloro-N,N,5-trimethylpyridine-3-carboxamide
• CAS: 178672-20-3
• 化学式: C₉H₁₁ClN₂O
• 分子量: 198.652
• InChiKey: KIAPVODWNUQKCK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  33.2
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2-chloro-5-iodo-N,N-dimethylnicotinamide 、 碘甲烷 在 叔丁基锂 作用下， 以 四氢呋喃 为溶剂， 生成 2-chloro-N,N,5-trimethylnicotinamide
  参考文献：
  名称：

  \x9b3-(4-phenylpiperazin-1-yl)propyl-amino, thio and oxy!-pyridine,

  摘要：

  本发明涉及以下式I的新型α1-肾上腺素受体拮抗剂：##STR1## 其中：p为0或1；t为0, 1或2；X为O、S或NR.sup.6（其中R.sup.6为羟基或（C.sub.1-6）烷基）；Y和Z独立地为CH或N；R.sup.1为羟基、羟基、卤素、硝基、氨基、氰基、（C.sub.1-4）烷基硫基、乙酰氨基、三氟乙酰氨基、甲磺酰氨基、（C.sub.1-6）烷基、（C.sub.3-6）环烷基、（C.sub.3-6）环烷基（C.sub.1-4）烷基、噁唑-2-基、芳基、杂环芳基、芳基（C.sub.1-4）烷基、杂环芳基（C.sub.1-4）烷基、（C.sub.1-6）烷氧基、（C.sub.3-6）环烷氧基、（C.sub.3-6）环烷基（C.sub.1-4）烷氧基、2-丙炔氧基、芳氧基、杂环芳氧基、芳基（C.sub.1-4）烷氧基或杂环芳基（C.sub.1-4）烷氧基（其中烷基可选择性地用1至3个卤原子取代，芳基或杂环芳基可选择性地用1至2个独立选择的卤素和氰基取代）；R.sup.2为羟基、羟基、卤素、氰基、（C.sub.1-6）烷基或（C.sub.1-6）烷氧基（其中烷基可选择性地用1至3个卤原子取代）；R.sup.3为-C（O）R.sup.7（其中R.sup.7为（C.sub.1-6）烷基、（C.sub.3-6）环烷基、二（C.sub.1-4）烷基氨基、N-（C.sub.1-4）烷基-N-（C.sub.1-4）烷氧基氨基、（C.sub.1-4）烷基（（C.sub.1-4）烷氧基）氨基、吡咯烷-1-基、哌啶-1-基、吗啉-4-基或哌嗪-1-基）；R.sup.4为卤素、羟基、氰基、（C.sub.1-6）烷基或（C.sub.1-6）烷氧基；R.sup.5为（C.sub.1-6）烷基；以及其药学上可接受的盐和N-氧化物。

  公开号：

  US05688795A1

文献信息

• 3-(4-phenylpiperazin-1-yl)propyl-amino, thio and oxy -pyridine, pyrimidine and benzene derivatives as alpha1-adrenoceptor antagonists
  申请人：F. Hoffmann-La Roche AG

  公开号：EP0711757A1

  公开（公告）日：1996-05-15

  The present invention relates to novel α₁-adrenoceptor antagonists of Formula I: in which: p is 0 or 1; t is 0, 1 or 2; X is O, S or NR⁶ (in which R⁶ is hydro or (C₁₋₆)alkyl); Y and Z are independently CH or N; R¹ is hydro, hydroxy, halo, nitro, amino, cyano, (C₁₋₄)alkylthio, acetylamino, trifluoroacetylamino, methylsulfonylamino, (C₁₋₆)alkyl, (C₃₋₆)cycloalkyl, (C₃₋₆)cycloalkyl(C₁₋₄)alkyl, oxazol-2-yl, aryl, heteroaryl, aryl(C₁₋₄)alkyl, heteroaryl(C₁₋₄)alkyl, (C₁₋₆)alkyloxy, (C₃₋₆)cycloalkyloxy, (C₃₋₆)cycloalkyl(C₁₋₄)alkyloxy, 2-propynyloxy, aryloxy, heteroaryloxy, aryl(C₁₋₄)alkyloxy or heteroaryl(C₁₋₄)alkyloxy (wherein alkyl is optionally substituted with one to three halo atoms and aryl or heteroaryl is optionally substituted with one to two substituents independently selected from halo and cyano); R² is hydro, hydroxy, halo, cyano, (C₁₋₆)alkyl or (C₁₋₆)alkyloxy (wherein alkyl is optionally substituted with one to three halo atoms); R³ is -C(O)R⁷ (wherein R⁷ is (C₁₋₆)alkyl, (C₃₋₆)cycloalkyl, di(C₁₋₄)alkylamino, N-(C₁₋₄)alkyl-N-(C₁₋₄)alkyloxyamino, (C₁₋₄)alkyl((C₁₋₄)alkyloxy)amino, pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl or piperazin-1-yl); R⁴ is halo, hydroxy, cyano, (C₁₋₆)alkyl or (C₁₋₆)alkyloxy; and R⁵ is (C₁₋₆)alkyl; and the pharmaceutically acceptable salts and N-oxides thereof.

  本发明涉及式 I 的新型 α₁-肾上腺素受体拮抗剂： 其中 p 是 0 或 1； t 是 0、1 或 2 X 是 O、S 或 NR⁶（其中 R⁶ 是氢或 (C₁₋₆)烷基）； Y 和 Z 独立地为 CH 或 N； R¹是氢、羟基、卤代、硝基、氨基、氰基、(C₁₋₄)烷硫基、乙酰氨基、三氟乙酰氨基、甲磺酰氨基、(C₁₋₆)烷基、(C₃₋₆)环烷基、(C₃₋₆)环烷基(C₁₋₄)烷基、噁唑-2-基、芳基、杂芳基、芳基(C₁₋₄)烷基、杂芳基(C₁₋₄)烷基、(C₁₋₆)烷氧基、(C₃₋₆)环烷氧基、(C₃₋₆)环烷基(C₁₋₄)烷氧基，2-丙炔氧基，芳基氧基，杂芳基氧基、芳基（C₁₋₄）烷氧基或杂芳基（C₁₋₄）烷氧基（其中烷基任选被一至三个卤原子取代，芳基或杂芳基任选被一至两个独立选自卤素和氰基的取代基取代）； R² 是氢、羟基、卤代、氰基、(C₁₋₆)烷基或(C₁₋₆)烷氧基（其中烷基任选被一至三个卤原子取代）； R³ 是 -C(O)R⁷（其中 R⁷ 是 (C₁₋₆)烷基、(C₃₋₆)环烷基、二(C₁₋₄)烷基氨基、N-(C₁₋₄)烷基-N-(C₁₋₄)烷氧基氨基、(C₁₋₄)烷基((C₁₋₄烷氧基)氨基、吡咯烷-1-基、哌啶-1-基、吗啉-4-基或哌嗪-1-基)； R⁴ 是卤素、羟基、氰基、(C₁₋₆)烷基或 (C₁₋₆)烷氧基；和 R⁵ 是 (C₁₋₆)烷基；及其药学上可接受的盐和 N-氧化物。
• US5688795A
  申请人：——

  公开号：US5688795A

  公开（公告）日：1997-11-18
• \x9b3-(4-phenylpiperazin-1-yl)propyl-amino, thio and oxy!-pyridine,
  申请人：Syntex (U.S.A.) Inc.

  公开号：US05688795A1

  公开（公告）日：1997-11-18

  The present invention relates to novel .alpha..sub.1 -adrenoceptor antagonists of Formula I: ##STR1## in which: p is 0 or 1; t is 0, 1 or 2; X is O, S or NR.sup.6 (in which R.sup.6 is hydro or (C.sub.1-6)alkyl); Y and Z are independently CH or N; R.sup.1 is hydro, hydroxy, halo, nitro, amino, cyano, (C.sub.1-4)alkylthio, acetylamino, trifluoroacetylamino, methylsulfonylamino, (C.sub.1-6)alkyl, (C.sub.3-6)cycloalkyl, (C.sub.3-6)cycloalkyl (C.sub.1-4)alkyl, oxazol-2-yl, aryl, heteroaryl, aryl (C.sub.1-4)alkyl, heteroaryl (C.sub.1-4)alkyl, (C.sub.1-6)alkyloxy, (C.sub.3-6)cycloalkyloxy, (C.sub.3-6)cycloalkyl (C.sub.1-4)alkyloxy, 2-propynyloxy, aryloxy, heteroaryloxy, aryl (C.sub.1-4)alkyloxy or heteroaryl (C.sub.1-4)alkyloxy (wherein alkyl is optionally substituted with one to three halo atoms and aryl or heteroaryl is optionally substituted with one to two substituents independently selected from halo and cyano); R.sup.2 is hydro, hydroxy, halo, cyano, (C.sub.1-6)alkyl or (C.sub.1-6)alkyloxy (wherein alkyl is optionally substituted with one to three halo atoms); R.sup.3 is -C (O)R.sup.7 (wherein R.sup.7 is (C.sub.1-6)alkyl, (C.sub.3-6)cycloalkyl, di(C.sub.1-4)alkylamino, N-(C.sub.1-4)alkyl-N-(C.sub.1-4)alkyloxyamino, (C.sub.1-4)alkyl((C.sub.1-4)alkyloxy)amino, pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl or piperazin-1-yl); R.sup.4 is halo, hydroxy, cyano, (C.sub.1-6)alkyl or (C.sub.1-6)alkyloxy; and R.sup.5 is (C.sub.1-6)alkyl; and the pharmaceutically acceptable salts and N-oxides thereof.

  本发明涉及以下式I的新型α1-肾上腺素受体拮抗剂：##STR1## 其中：p为0或1；t为0, 1或2；X为O、S或NR.sup.6（其中R.sup.6为羟基或（C.sub.1-6）烷基）；Y和Z独立地为CH或N；R.sup.1为羟基、羟基、卤素、硝基、氨基、氰基、（C.sub.1-4）烷基硫基、乙酰氨基、三氟乙酰氨基、甲磺酰氨基、（C.sub.1-6）烷基、（C.sub.3-6）环烷基、（C.sub.3-6）环烷基（C.sub.1-4）烷基、噁唑-2-基、芳基、杂环芳基、芳基（C.sub.1-4）烷基、杂环芳基（C.sub.1-4）烷基、（C.sub.1-6）烷氧基、（C.sub.3-6）环烷氧基、（C.sub.3-6）环烷基（C.sub.1-4）烷氧基、2-丙炔氧基、芳氧基、杂环芳氧基、芳基（C.sub.1-4）烷氧基或杂环芳基（C.sub.1-4）烷氧基（其中烷基可选择性地用1至3个卤原子取代，芳基或杂环芳基可选择性地用1至2个独立选择的卤素和氰基取代）；R.sup.2为羟基、羟基、卤素、氰基、（C.sub.1-6）烷基或（C.sub.1-6）烷氧基（其中烷基可选择性地用1至3个卤原子取代）；R.sup.3为-C（O）R.sup.7（其中R.sup.7为（C.sub.1-6）烷基、（C.sub.3-6）环烷基、二（C.sub.1-4）烷基氨基、N-（C.sub.1-4）烷基-N-（C.sub.1-4）烷氧基氨基、（C.sub.1-4）烷基（（C.sub.1-4）烷氧基）氨基、吡咯烷-1-基、哌啶-1-基、吗啉-4-基或哌嗪-1-基）；R.sup.4为卤素、羟基、氰基、（C.sub.1-6）烷基或（C.sub.1-6）烷氧基；R.sup.5为（C.sub.1-6）烷基；以及其药学上可接受的盐和N-氧化物。